FDA Recalls 3.1 Million Sterile Eye Drop Bottles: Brands, Health Risks, and Expert Advice

In early March 2025, a California-based pharmaceutical company, K.C. Pharmaceuticals, quietly initiated a voluntary recall that has since grabbed the attention of millions of Americans. The affected products—more than 3.1 million bottles of multiple private-label eye drop formulas—were distributed through major national chains including Walgreens, Kroger, and CVS. On March 31, the U.S. Food and Drug Administration formally classified the action as a Class II recall, a designation indicating that using the product could cause temporary or medically reversible health consequences, though the probability of a serious event is remote. For eye drop users still rattled by a deadly 2023 bacterial outbreak, the sheer scale of this recall has renewed anxiety about the safety of over-the-counter ocular products.

Background: A Fragile Trust in Over-the-Counter Eye Drops

The eye drop aisle has not been a comfortable place for many shoppers in recent years. In early 2023, the United States witnessed one of the worst drug-related infectious outbreaks in memory. Contaminated bottles of EzriCare and Delsam Pharma artificial tears were linked to a rare, extensively drug-resistant strain of Pseudomonas aeruginosa. By the time the outbreak was contained, the Centers for Disease Control and Prevention had tallied more than 80 infections across 18 states, 14 cases of permanent vision loss, and four deaths. Many patients required months of intravenous antibiotic therapy, and some underwent corneal transplants. The episode forced the FDA to overhaul its oversight of imported OTC eye products and left a residue of suspicion that has not fully dissipated.

Over-the-counter eye drops are regulated differently than prescription medications. Prescription drops for conditions like glaucoma or severe dry eye undergo pre-market FDA review for safety and efficacy. Over-the-counter artificial tears and redness relievers, however, are marketed without that pre-approval process, provided manufacturers comply with Current Good Manufacturing Practice (CGMP) regulations designed to guarantee sterility, purity, and quality. This regulatory gap means that much of the vigilance falls on manufacturing site inspections and post-market surveillance. When those inspections catch a problem—or when a manufacturer voluntarily discloses one—a recall becomes the primary safety net. The latest recall does not involve proof of contamination, but rather a “lack of assurance of sterility,” meaning that somewhere along the production line, a process deviation may have opened a door for microbes to enter.

The Evidence: What the Recall Actually Tells Us

The specifics of this recall come directly from the FDA’s enforcement report and interviews with two independent eye care experts. The recall was initiated by K.C. Pharmaceuticals on March 3, 2025, and covers eight distinct product labels, all manufactured in a single facility and sold under store brands at CVS, Walgreens, Kroger, and possibly other retailers. The full list of recalled products includes: Sterile Eye Drops AC, Eye Drops Advanced Relief, Dry Eye Relief Eye Drops, Ultra Lubricating Eye Drops, Sterile Eye Drops Original Formula, Sterile Eye Drops Redness Lubricant, Sterile Eye Drops Soothing Tears, and Artificial Tears Sterile Lubricant Eye Drops. Together, more than 3.1 million bottles are affected—a number that gives a sense of the national distribution footprint.

Gary Novack, PhD, a clinical professor in the UC Davis Department of Ophthalmology and Vision Science and a consultant in ophthalmic product development, stressed that the recall rests on potential, not proven, contamination. “We don’t know if they really were contaminated. If they were, we don’t know what type of microbe. We don’t know any of that. All we know is that the manufacturer said there’s an issue with sterility in these products,” Novack said. The FDA classified the recall as Class II, which the agency defines as a situation where “the probability of a serious health issue is remote.” This is not a Class I recall (reasonable probability of serious adverse health consequences or death), but it is also not trivial. The label “lack of assurance of sterility” suggests that during a routine audit or internal review, the manufacturer identified a deviation from CGMP standards—perhaps involving environmental monitoring, filter integrity, or aseptic filling procedures—that could theoretically allow bacterial or fungal contamination.

No illnesses have been reported to date. A CVS representative told Healthline that the four recalled items sold by CVS were discontinued nearly a year ago, though the company is fully cooperating with the voluntary recall. Walgreens and Kroger did not respond to requests for comment. The researchers did not report a specific study linked to this recall—the recall itself is the regulatory action—but Novack was an author on a 2023 commentary in the journal Ophthalmology analyzing the earlier outbreak. That piece documented how a contaminated manufacturing facility for EzriCare drops went undetected partly because the FDA temporarily paused domestic and foreign inspections during the COVID-19 pandemic, creating a “perfect storm” of failures. This historical context makes sterility lapses more than a theoretical concern.

What This Means for You

If you have purchased generic store-brand artificial tears or redness-relief drops from CVS, Walgreens, or Kroger in the past year, check your medicine cabinet now. Compare the product name on the bottle against the list of eight recalled formulas. Do not use any bottle that matches, even if the liquid looks clear and the bottle is unopened. The FDA and retailers advise consumers to discard the product safely and return it to the place of purchase for a full refund. Prescription eye drops for glaucoma, dry eye, or infection are completely unaffected by this recall, and both Novack and Sylvia Groth, MD, executive medical director of the Department of Ophthalmology at Vanderbilt University Medical Center, emphasized that patients should continue their prescribed treatments without interruption. “They’re not at risk,” Novack said. “We don’t want patients to stop using their prescription eye drops. It doesn’t apply to them.”

Watch for symptoms of eye infection over the next few days and weeks, especially if you have used a recalled product recently. Signs to look for include yellow or green discharge, eye pain or a gritty sensation, unusual redness or swelling of the eyelid, and blurry vision that doesn’t improve with blinking. Groth noted that these symptoms can be nonspecific, especially during allergy season, but the key is persistence and progression. “If it is actually an allergy-based reaction, that can be bothersome and irritating, but not something that needs any additional treatment or antibiotics,” she said. “Track symptom progression, and if they aren’t improving, it may be time to see a doctor.” People who wear contact lenses should be particularly cautious, as small corneal abrasions can make the eye more vulnerable to bacterial invasion, and contact lenses can harbor organisms that an otherwise healthy eye would fight off.

Expert Perspective: Trust, Transparency, and Hygiene

Beyond the bottle-by-bottle recall, experts worry about the slow erosion of confidence in over-the-counter eye care. “It’s always concerning any time we have a recall of clinical products,” Groth said. “These events erode patient trust in over-the-counter medications. I am concerned that when I prescribe or recommend a treatment, it can be undermined by a recall.” Both Groth and Novack underscored that the recall itself is a sign that the safety net is working—a potential problem was identified and disclosed before it spiraled into a public health crisis. Still, until the FDA and manufacturers can fully trace the sterility lapse and verify that no contaminated bottles reached store shelves, a degree of caution is warranted. Further research is needed to understand whether current CGMP enforcement is sufficient in an era of global supply chains, and whether more frequent unannounced inspections could catch sterility failures before they trigger mass recalls. The 2023 outbreak demonstrated that even one lapse can carry a devastating human cost, and the current recall reminds everyone—regulators, companies, and consumers—that sterility is a fragile and non-negotiable attribute of any product introduced directly onto the surface of the eye.

Frequently Asked Questions

Q: Which specific eye drop brands are included in the recall?

The recall covers eight store-brand products distributed by K.C. Pharmaceuticals: Sterile Eye Drops AC, Eye Drops Advanced Relief, Dry Eye Relief Eye Drops, Ultra Lubricating Eye Drops, Sterile Eye Drops Original Formula, Sterile Eye Drops Redness Lubricant, Sterile Eye Drops Soothing Tears, and Artificial Tears Sterile Lubricant Eye Drops. These were sold at CVS, Walgreens, Kroger, and possibly other retailers. If your bottle matches one of these names, stop using it immediately.

Q: Has anyone gotten sick from these recalled eye drops?

No. As of the latest FDA update, there have been zero reported injuries, infections, or illnesses linked to these products. The recall was triggered by a potential sterility lapse discovered during the manufacturing process, not by a cluster of patient infections. The FDA’s Class II designation means the chance of a serious health problem is considered remote, but the recall is being conducted out of an abundance of caution to prevent a worst-case scenario.

Q: How do I know if I have an eye infection from contaminated drops?

Typical symptoms include discharge (yellow, green, or watery), pain or discomfort that feels like a foreign body in the eye, redness affecting the white of the eye or inner eyelid, and blurry vision that doesn’t go away after blinking. These signs can mimic severe allergies, so pay attention to whether symptoms worsen over 24 to 48 hours. If pain, discharge, or vision changes persist, contact an eye doctor promptly. Contact lens wearers should remove their lenses until evaluated.

Q: Are prescription eye drops safe to use right now?

Yes. The recall applies exclusively to over-the-counter products manufactured by K.C. Pharmaceuticals. Prescription eye drops for glaucoma, chronic dry eye, infection, or post-surgical care are not affected and should be used exactly as your doctor prescribed. Stopping prescription drops without medical advice can lead to elevated eye pressure or flare-ups of underlying disease. If you have concerns, check the manufacturer name on your bottle, but there is no overlap with this recall.

Q: What should I do if I still have a recalled bottle at home?

Do not use it, even if the seal is intact and the liquid appears normal. The FDA and retailers recommend discarding the product in household trash, but keep the bottle or take a photo of the label if you want a refund. CVS has confirmed customers can return recalled products to the store for a full refund; Walgreens and Kroger are expected to follow the same policy. Wash your hands thoroughly after handling the bottle, and do not transfer the liquid to another container.

Q: How can I minimize infection risk when using any eye drops?

Always wash your hands before applying drops. Avoid touching the dropper tip to your eye, eyelashes, or any surface—contamination of the tip is a common route for bacteria to enter the bottle. Replace the cap tightly immediately after use. If you are using single-dose preservative-free vials, discard them right after the first application, even if some liquid remains. Look for products from well-known manufacturers, and ask your eye doctor to recommend a brand that has a strong safety record.

Sources

• FDA Recall Report: K.C. Pharmaceuticals Voluntary Recall (March 2025). Accessdata.fda.gov, Event #98533.
• Gary Novack, PhD, clinical professor, UC Davis Department of Ophthalmology and Vision Science, interviewed by Healthline.
• Sylvia Groth, MD, executive medical director, Department of Ophthalmology, Vanderbilt University Medical Center, interviewed by Healthline.
• Novack GD et al. (2023). Commentary on the 2023 Pseudomonas aeruginosa outbreak linked to artificial tears. Ophthalmology. DOI: 10.1016/j.ophtha.2023.08.021
• CDC (2023). Multistate Outbreak of Extensively Drug-Resistant Pseudomonas aeruginosa Associated with Artificial Tears.
• FDA Recalls Background and Definitions: Class II recall definition.